Premier Anti-Aging Co., Ltd. (4934) AI Stock Analysis

• Market Cap: ¥6.13B
• Dividend Yield: N/A
• Average Volume (3M): 11.01K
• Price to Earnings (P/E): 13.2
• Beta (1Y): 1.00
• Revenue Growth: -19.42%
• EPS Growth: N/A
• Country: JP
• Employees: 229
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 46.82
• Shares Outstanding: 8,720,534
• 10 Day Avg. Volume: 8,960
• 30 Day Avg. Volume: 11,006
• PEG Ratio: -0.12
• Price to Book (P/B): 1.14
• Price to Sales (P/S): 0.47
• P/FCF Ratio: 5.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: ¥743.00 ▲(5.84% Upside)

The overall stock score is primarily impacted by the company's financial performance, which shows strengths in gross profit margin and balance sheet stability but is hindered by declining revenues and low profitability. Technical analysis indicates bearish momentum, further weighing down the score. Valuation is a relative strength, with a reasonable P/E ratio, but the lack of a dividend yield is a drawback.

Positive Factors

Gross Profit Margin

A strong gross profit margin indicates efficient production processes, allowing the company to maintain profitability despite revenue challenges.

Balance Sheet Stability

A stable balance sheet with low leverage provides financial flexibility and reduces risk, supporting long-term business sustainability.

Cash Flow Improvement

Improved cash flow conversion enhances liquidity and supports reinvestment in growth initiatives, strengthening the company's financial position.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in market demand or competitive pressures, which could impact long-term growth and market position.

Low Net Profit Margin

A low net profit margin suggests difficulties in cost control or pricing power, potentially limiting profitability and financial health over time.

Operational Efficiency

Limited operational efficiency can hinder profitability improvements and competitiveness, affecting the company's ability to scale effectively.

Premier Anti-Aging Co., Ltd. Business Overview & Revenue Model

Company Description

Premier Anti-Aging Co., Ltd. engages in the planning, development, import/export, mail order, wholesale, and retail business of cosmetics and health foods. The company offers its cosmetic products under the DUO and CANADEL brands. It is also involved on the information provision and consulting services related to anti-aging, beauty, and health; research on management and beauty of beauty clinics, etc.; and marketing research and collection and analysis of various information. The company was founded in 2009 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Premier Anti-Aging Co., Ltd. generates revenue primarily through the sale of its anti-aging skincare products and dietary supplements. The company employs a multi-channel distribution strategy, selling its products through e-commerce platforms, retail partnerships with beauty stores, and direct-to-consumer channels. Key revenue streams include online sales, wholesale partnerships with beauty retailers, and subscription services for regular customers. Additionally, the company may engage in strategic partnerships with dermatologists and beauty influencers to enhance its market presence and drive product visibility, contributing significantly to its earnings.

Premier Anti-Aging Co., Ltd. Financial Statement Overview

Summary

Premier Anti-Aging Co., Ltd. shows a strong gross profit margin and a stable balance sheet with low leverage. However, declining revenues and low net profit margins are concerning. Cash flow has improved, but operational efficiency needs enhancement to boost profitability.

Income Statement

Premier Anti-Aging Co., Ltd. has experienced declining revenue over the past few years, with a negative revenue growth rate of -7.23% in the most recent year. The gross profit margin remains strong at 76.65%, indicating efficient production processes. However, the net profit margin is low at 2.91%, reflecting challenges in controlling costs or increasing sales. The EBIT and EBITDA margins are also low, suggesting limited operational efficiency and profitability.

Balance Sheet

The company's balance sheet shows a stable debt-to-equity ratio of 0.17, indicating conservative leverage. The return on equity is moderate at 7.13%, suggesting reasonable profitability from shareholders' investments. The equity ratio is healthy, reflecting a solid capital structure with a good proportion of equity financing.

Cash Flow

Cash flow analysis reveals a significant improvement in free cash flow, with a growth rate of 'Infinity' due to a previous negative base. The operating cash flow to net income ratio is 0.49, indicating moderate cash generation relative to net income. The free cash flow to net income ratio is high at 0.98, suggesting effective conversion of profits into cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.16B	16.16B	20.36B	26.40B	33.91B	32.81B
Gross Profit	12.39B	12.39B	16.10B	19.24B	26.63B	26.43B
EBITDA	876.00M	916.00M	-627.00M	-432.24M	2.67B	4.71B
Net Income	471.00M	471.00M	-1.48B	-733.97M	1.42B	2.79B
Balance Sheet
Total Assets	10.14B	10.14B	11.00B	12.14B	12.30B	13.07B
Cash, Cash Equivalents and Short-Term Investments	4.66B	4.66B	4.76B	4.67B	2.97B	6.06B
Total Debt	1.11B	1.11B	2.44B	2.26B	1.41B	911.41M
Total Liabilities	3.53B	3.53B	4.88B	4.53B	3.95B	6.17B
Stockholders Equity	6.61B	6.61B	6.12B	7.61B	8.35B	6.90B
Cash Flow
Free Cash Flow	0.00	1.44B	-395.00M	1.64B	-3.53B	2.68B
Operating Cash Flow	0.00	1.47B	425.00M	2.42B	-3.32B	2.75B
Investing Cash Flow	0.00	-229.00M	-540.00M	-900.97M	-297.68M	-180.83M
Financing Cash Flow	0.00	-1.34B	183.00M	179.77M	501.62M	1.58B

Premier Anti-Aging Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 702.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4934, the sentiment is Negative. The current price of 702 is above the 20-day moving average (MA) of 700.05, below the 50-day MA of 703.86, and below the 200-day MA of 816.34, indicating a neutral trend. The MACD of 0.86 indicates Negative momentum. The RSI at 49.14 is Neutral, neither overbought nor oversold. The STOCH value of 61.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4934.

Premier Anti-Aging Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4925	63 Neutral	¥6.50B	8.33	―	2.38%	-0.79%	―
4936	63 Neutral	¥9.72B	25.59	―	2.65%	11.87%	-31.02%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
4929	60 Neutral	¥6.19B	160.42	―	1.59%	-9.99%	-35.06%
4926	58 Neutral	¥5.27B	16.86	―	1.68%	8.46%	―
4934	52 Neutral	¥6.13B	13.18	―	―	-19.42%	―
4935	49 Neutral	¥9.59B	-67.43	―	0.48%	10.13%	-14654.18%

Premier Anti-Aging Co., Ltd. Corporate Events

Premier Anti-Aging Reports Decline in Q1 Financial Results

Premier Anti-Aging Co., Ltd. reported a decline in its financial performance for the first three months of the fiscal year ending July 31, 2026, with net sales dropping by 13.9% compared to the previous year. Despite the decrease in sales and profits, the company’s equity ratio improved slightly, indicating a stable financial position, although the outlook for the fiscal year remains cautious.

The most recent analyst rating on (JP:4934) stock is a Hold with a Yen743.00 price target. To see the full list of analyst forecasts on Premier Anti-Aging Co., Ltd. stock, see the JP:4934 Stock Forecast page.

Premier Anti-Aging Finalizes Stock Option Issuance

Premier Anti-Aging Co., Ltd. has finalized the conditions for issuing stock options to its directors and executive officers, as decided in a recent board meeting. This move involves the allocation of 400 stock acquisition rights, translating to 40,000 common shares, which could impact the company’s equity structure and align management interests with shareholder value.

The most recent analyst rating on (JP:4934) stock is a Hold with a Yen743.00 price target. To see the full list of analyst forecasts on Premier Anti-Aging Co., Ltd. stock, see the JP:4934 Stock Forecast page.

Premier Anti-Aging Co., Ltd. Issues Stock Options to Boost Leadership Engagement

Premier Anti-Aging Co., Ltd. has announced the issuance of stock options to its directors and executive officers as a strategic move to align their interests with shareholders and boost corporate performance. This initiative is designed to motivate leadership by allowing them to share in the benefits and risks of stock price fluctuations, potentially enhancing the company’s medium- to long-term value.

The most recent analyst rating on (JP:4934) stock is a Hold with a Yen743.00 price target. To see the full list of analyst forecasts on Premier Anti-Aging Co., Ltd. stock, see the JP:4934 Stock Forecast page.